Managing weight is a challenge for many, especially those with obesity or related health conditions. While diet and exercise are essential, they don’t always lead to the desired results. Biological factors like insulin resistance and hormonal imbalances can make long-term weight loss more difficult than it seems.
The CDC reports that nearly 74% of US adults are classified as overweight, with obesity-related conditions ranking among the leading causes of preventable death. Despite the increasing availability of weight management resources, many people still struggle to find effective solutions.
Rybelsus, an oral medication developed for type 2 diabetes, has gained attention for its potential role in weight loss. This article explores Rybelsus for weight loss, how it works, its benefits and risks, and key considerations for those thinking about using it.
Can Rybelsus Be Used for Weight Loss?
Using Rybelsus for weight loss is considered off-label prescribing, meaning a doctor recommends it for a purpose not officially approved by regulatory bodies like the FDA. This practice is common in medicine, with about 20% of prescriptions written for off-label use.
Physicians base these decisions on their clinical judgment and understanding of your condition. If your doctor suggests Rybelsus for weight loss, consider asking:
-
- What makes Rybelsus a suitable option for me?
-
- How does it compare to other weight management treatments?
-
- What potential side effects or risks should I be aware of?
-
- Have you observed successful outcomes in other patients using Rybelsus off-label?
If you’re unsure, seeking a second opinion from an endocrinologist or weight management specialist can provide further insight. They may confirm its suitability for your case or suggest alternatives.
Additionally, FDA-approved weight loss medications like Saxenda, Wegovy, or Contrave could be worth exploring to ensure the best approach for your health goals.
Is Rybelsus Approved for Weight Loss?
No, Rybelsus is not FDA-approved for weight loss. It is officially indicated for improving blood sugar control in adults with type 2 diabetes. However, because it contains semaglutide, the same active ingredient as Ozempic (which is sometimes used off-label for weight loss), many people taking Rybelsus for diabetes experience weight loss as a side effect.
This has led to its nickname, the “Ozempic pill.”
If you’re specifically looking for an FDA-approved semaglutide option for weight management, Wegovy is the recommended choice. It contains the same active ingredient as Rybelsus and Ozempic but is FDA-approved for chronic weight management.
How Does Rybelsus Work for Weight Loss?
Rybelsus supports weight loss by mimicking a natural hormone called glucagon-like peptide-1 (GLP-1). While its primary role is to regulate blood sugar, GLP-1 also slows digestion, helping you feel full longer and reducing the urge to overeat.
Beyond digestion, Rybelsus may also affect hunger signals in the brain.
A 2020 study found that semaglutide, the active ingredient in Rybelsus, activated 10 brain regions involved in hunger and food intake regulation. One key area appeared to influence meal size, suggesting that semaglutide helps control portion intake. Semaglutide-treated rats also showed increased levels of hormones and enzymes linked to appetite regulation.
Similarly, separate studies found that rats given semaglutide had less motivation for sugar and consumed less chocolate, indicating an effect on cravings and reward-based eating.
These findings suggest that Rybelsus promotes weight loss not just by stimulating GLP-1 receptors, but also by influencing brain pathways that regulate hunger, cravings, and metabolism.
How Long Does Rybelsus Take to Work?
For weight loss, the timeline varies. Some people notice subtle changes in appetite and portion sizes within a few weeks, but significant weight loss usually takes a few months.
In one study, Rybelsus was found to slow stomach emptying within the first hour after eating. After 12 weeks of treatment, participants ate less, had better control over their eating, lost weight, and experienced fewer food cravings.
Another study looked at the effectiveness and safety of Rybelsus in real-world practice. Results showed that Rybelsus led to substantial weight loss over time.
-
- At 6 months, participants lost an average of 32.6 lbs (~13.0% decrease in body weight).
- At 12 months, weight loss increased to 49.4 lbs (~19.7% reduction in body weight).
However, individual results vary. Some may start losing weight within a few weeks, while others might take several months to see noticeable changes. Factors like diet, exercise, and dosage can influence how quickly Rybelsus works for weight management.
Rybelsus Weight Loss Results
Research on Rybelsus’ weight loss effects in people without diabetes is limited, but clinical trials in those with type 2 diabetes have shown noticeable results.
Rybelsus 3 mg Weight Loss
The 3 mg dose of Rybelsus is primarily intended to help your body adjust to the medication rather than serve as a long-term weight management option. Because of this, weight loss at this dose tends to be minimal.
In clinical trials (PIONEER 1, 3, 4, and 8), weight loss with 3 mg ranged from 0.66 lbs to 1.98 lbs over 26 weeks. Since this is only a starting dose, more significant weight loss is typically observed with higher doses like 7 mg and 14 mg.
This aligns with what some users have reported about their experience with Rybelsus in online forums like Reddit.
One user shared that while taking 3 mg, they experienced appetite suppression for about 10 days and lost 4 lbs. However, their appetite returned after that period, and their weight loss stalled. Unfortunately, they couldn’t increase to 7 mg because their insurance wouldn’t cover it.
Another user had a different experience, reporting no side effects, no appetite suppression, and no weight loss after taking 3 mg for an entire month.
These personal experiences highlight how weight loss results with 3 mg of Rybelsus can vary widely among individuals.
Rybelsus 7 mg Weight Loss
The weight loss effects become more noticeable when you move up to the 7 mg dose. Data from clinical trials show weight reductions ranging from 1.32 lbs to 5.07 lbs at 26 weeks.
-
- In PIONEER 1, patients lost an average of 1.98 lbs over 26 weeks, compared to placebo.
-
- In PIONEER 3, patients on 7 mg of Rybelsus lost an average of 3.52 lbs, with a range between 2.43 lbs to 4.41 lbs over 26 weeks.
Rybelsus 14 mg Weight Loss
The 14 mg dose delivers the most weight loss, with studies showing reductions between 5.29 lbs and 6.83 lbs at 26 weeks. Some research suggests that the longer you stay on this dose, the more weight you may lose, especially beyond the 26-week mark.
Here’s a summary of the weight loss results from PIONEER trials:?
| Trial | Average Weight Loss (14 mg Rybelsus) | Duration |
|---|---|---|
| PIONEER 1 | 2.3 kg (5.1 lbs) | 26 weeks |
| PIONEER 2 | 4.7 kg (10.4 lbs) | 52 weeks |
| PIONEER 3 | 2.5 kg (5.51 lbs) | 26 weeks |
| PIONEER 4 | 4.4 kg (9.7 lbs) | 26 weeks |
| PIONEER 5 | 3.7 kg (8.1 lbs) | 26 weeks |
| PIONEER 8 | 3.3 kg (7.3 lbs) | 26 weeks |
The variation in weight loss results with Rybelsus stems from several factors, including participants’ baseline weight, existing health conditions, and additional treatments.
In some studies, Rybelsus was used alongside insulin, which may have influenced outcomes. It’s also important to note that these studies were conducted in individuals with type 2 diabetes.
What is the Recommended Rybelsus Dosage for Weight Loss?
If prescribed off-label for weight management, Rybelsus’ dosing for weight loss follows the same dosing schedule as for diabetes:
-
- Start with 3 mg once daily for the first 30 days (to help your body adjust).
- Increase to 7 mg once daily for at least 30 more days.
- If needed for better results, increase to 14 mg once daily.
Although, in December 2024, Rybelsus’ prescribing information was updated to include additional dosage strengths, expanding its available formulations:
| Formulation | Available Strengths |
|---|---|
| Rybelsus R1 (Original) | 3 mg, 7 mg, 14 mg |
| Rybelsus R2 (New) | 1.5 mg, 4 mg, 9 mg |
A 2024 bioequivalence study confirmed that the new Rybelsus R2 formulation is as safe and effective as the original Rybelsus R1 for reducing HbA1c and body weight. This means patients can switch between formulations when necessary.
If switching between formulations, follow these guidelines:
-
- Do not switch formulations during the first 30 days of treatment (the initiation phase).
- Once you’ve completed 30 days, you may transition to a different formulation.
- To switch, stop your current formulation and start the new one the next day, but never take both formulations at the same time.
Equivalent dosages when switching:
| If You Take (R1) | Switch To (R2) |
|---|---|
| 7 mg once daily | 4 mg once daily |
| 14 mg once daily | 9 mg once daily |
Keep in mind that the two formulations are not equivalent on a milligram-to-milligram basis, they cannot be directly substituted. You should use only one formulation at a time, either Rybelsus R1 or R2, but never both simultaneously.
How to Use Rybelsus for Weight Loss?
Take Rybelsus in the morning on an empty stomach with up to 4 ounces of water, avoiding other liquids. After taking the tablet, wait at least 30 minutes before eating, drinking, or taking any other medications. Swallow it whole without splitting, crushing, or chewing.
What are the Side Effects of Rybelsus When Used for Weight Loss?
The side effects of Rybelsus for weight loss are generally the same as those experienced when used for type 2 diabetes. Since Rybelsus slows digestion and regulates appetite, common side effects like nausea, vomiting, diarrhea, constipation, and abdominal pain occur regardless of whether it’s used for diabetes or weight loss.
Those with a history of pancreatitis, thyroid cancer, or severe gastrointestinal issues may not be able to use Rybelsus, as it has been linked to an increased risk of pancreatitis, potential thyroid tumor growth (in animal studies), and worsening digestive symptoms.
Takeaway
Rybelsus is not FDA-approved for weight loss, but it can help some people lose weight by reducing appetite and slowing digestion. Studies show that higher doses lead to more weight loss, but results vary.
If you’re considering Rybelsus for weight loss, it’s essential to talk to your doctor. Since it’s an off-label use, discussing the risks, benefits, and alternatives like Wegovy can help you make an informed choice.
Follow the correct dosing and administration guidelines, and be aware of possible side effects, especially digestive issues. Rybelsus may work for weight loss, but it’s not the best option for everyone.
FAQs About Rybelsus for Weight Loss
Related Articles
Sources
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Villegas, E. C. M., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., . . . Fitzgibbons, W. (2019). PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, 42(9), 1724–1732. https://doi.org/10.2337/dc19-0749
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., Cruz, P., De Loredo, L., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., . . . Wright, A. (2019). Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care, 42(12), 2272–2281. https://doi.org/10.2337/dc19-0883
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., & Davies, M. (2019). Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA, 321(15), 1466. https://doi.org/10.1001/jama.2019.2942
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet, 394(10192), 39–50. https://doi.org/10.1016/s0140-6736(19)31271-1
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., Alpenidze, D., Aronoff, S., Astamirova, K., Barker, B., Bedel, G., Belousova, L., Benson, M., Beshay, I., Biggs, W., . . . Zhdanova, E. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology, 7(7), 515–527. https://doi.org/10.1016/s2213-8587(19)30192-5
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., Zinman, B., Fikry, S., Bajaj, H., Landry, D., Caplan, D., Woo, V., Harris, S., Thuan, J., Serusclat, P., Cariou, B., . . . Buse, J. (2019). Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with Type 2 diabetes: the PIONEER 8 trial. Diabetes Care, 42(12), 2262–2271. https://doi.org/10.2337/dc19-0898
Araki, E., Terauchi, Y., Watada, H., Deenadayalan, S., Christiansen, E., Horio, H., & Kadowaki, T. (2021). Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes, obesity & metabolism, 23(12), 2785–2794. https://doi.org/10.1111/dom.14536
Nielsen, M. S., Brøndsted, L., Kankam, M., Morelli, G., Nguyen, D., Skjøth, T. V., Patted, U. R., & Van Hout, M. (2024). A bioequivalence study of two formulations of oral semaglutide in healthy participants. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01674-8
Knop, F. K., Aroda, V. R., Vale, R. D. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/s0140-6736(23)01185-6
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., Helms, H. C. C., Jeppesen, J. F., John, L. M., Pyke, C., Nøhr, J., Lu, T. T., Polex-Wolf, J., Prevot, V., Raun, K., . . . Knudsen, L. B. (2020b). Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight, 5(6). https://doi.org/10.1172/jci.insight.133429
Kooij, K. L., Koster, D. I., Eeltink, E., Luijendijk, M., Drost, L., Ducrocq, F., & Adan, R. A. (2023b). GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neuroscience Applied, 3, 103925. https://doi.org/10.1016/j.nsa.2023.103925
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021). A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs, 81(9), 1003–1030. https://doi.org/10.1007/s40265-021-01499-w
Alsheikh, A., Alshehri, A., Alzahrani, S., AlJammah, A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., Aljuhani, N., Aldabeis, A., Alamri, M., Maghawry, W., Alzaman, N., Alshaikh, A., Alnozha, O. M., Issak, E. R., & Alsifri, S. (2024). Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study. Diabetes Epidemiology and Management, 14, 100209. https://doi.org/10.1016/j.deman.2024.100209
Formichi, C., Baronti, W., de Gennaro, G., Cerrai Ceroni, M., Nigi, L., Rizzo, L., & Dotta, F. (2024). Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?. Journal of endocrinological investigation, 47(11), 2679–2690. https://doi.org/10.1007/s40618-024-02369-4
